Evidence map›Paper›PMID 20142324›Full record

ArticleThe Journal of biological chemistry2010

Transforming growth factor-β1 induces expression of human coagulation factor XII via Smad3 and JNK signaling pathways in human lung fibroblasts.

Ewa Jablonska, Philipp Markart, Dariusz Zakrzewicz, Klaus T Preissner, Malgorzata Wygrecka

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.

  1. Factor XII-A New Therapeutic Target? A Systematic Review.International journal of molecular sciences · 2026
    Pooled it
  2. Article
  3. Succinate aggravates pulmonary fibrosis through the succinate/SUCNR1 axis.American journal of physiology. Lung cellular and molecular physiology · 2025
    Article
  4. Article
  5. Review
  6. Microvascular significance of TGF-β axis activation in COVID-19.Frontiers in cardiovascular medicine · 2022
    Review
  7. The contact system in liver injury.Seminars in immunopathology · 2021
    Review
  8. Review
  9. Review
  10. Article
  11. Factor XII - What's important but not commonly thought about.Research and practice in thrombosis and haemostasis · 2019
    Review
  12. The TGFβ1 Receptor Antagonist GW788388 Reduces JNK Activation and Protects Against Acetaminophen Hepatotoxicity in Mice.Toxicological sciences : an official journal of the Society of Toxicology · 2019
    Article
  13. Article
  14. Article
  15. Article
  16. Rapamycin increases CCN2 expression of lung fibroblasts via phosphoinositide 3-kinase.Laboratory investigation; a journal of technical methods and pathology · 2015
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Ewa JablonskaDepartment of Biochemistry, Faculty of Medicine, Justus-Liebig University, 35392 Giessen, Germany.
Philipp Markart
Dariusz Zakrzewicz
Klaus T Preissner
Malgorzata Wygrecka
Giessen School of Theology · DEUniversity of Giessen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coagulation factor XII (FXII) is a liver-derived serine protease involved in fibrinolysis, coagulation, and inflammation. The regulation of FXII expression is largely unknown. Transforming growth factor-beta1 (TGF-beta1) is a multifunctional cytokine that has been linked to several pathological processes, including tissue fibrosis by modulating procoagulant and fibrinolytic activities. This study investigated whether TGF-beta1 may regulate FXII expression in human lung fibroblasts. Treatment of human lung fibroblasts with TGF-beta1 resulted in a time-dependent increase in FXII production, activation of p44/42, p38, JNK, and Akt, and phosphorylation and translocation into the nucleus of Smad3. However, TGF-beta1-induced FXII expression was repressed only by the JNK inhibitor and JNK and Smad3 antisense oligonucleotides but not by MEK, p38, or phosphoinositide 3-kinase blockers. JNK inhibition had no effect on TGF-beta1-induced Smad3 phosphorylation, association with Smad4, and its translocation into the nucleus but strongly suppressed Smad3-DNA complex formation. FXII promoter analysis revealed that the -299/+1 region was sufficient for TGF-beta1 to induce FXII expression. Sequence analysis of this region detected a potential Smad-binding element at position -272/-269 (SBE-(-272/-269)). Chromatin immunoprecipitation and streptavidin pulldown assays demonstrated TGF-beta1-dependent Smad3 binding to SBE-(-272/-269). Mutation or deletion of SBE-(-272/-269) substantially reduced TGF-beta1-mediated activation of the FXII promoter. Clinical relevance was demonstrated by elevated FXII levels and its co-localization with fibroblasts in the lungs of patients with acute respiratory distress syndrome. Our results show that JNK/Smad3 pathway plays a critical role in TGF-beta1-induced FXII expression in human lung fibroblasts and implicate its possible involvement in pathological conditions characterized by elevated TGF-beta1 levels.

Indexed as

Gene Expression RegulationAnimalsBronchoalveolar Lavage FluidFactor XIIFibroblastsHumansLungMiceMitogen-Activated Protein Kinase 8NIH 3T3 CellsOligonucleotides, AntisensePromoter Regions, GeneticRespiratory Distress SyndromeSignal TransductionSmad3 ProteinTransforming Growth Factor beta1Factor XIIMitogen-Activated Protein Kinase 8Oligonucleotides, AntisenseSmad3 ProteinSMAD3 protein, humanTransforming Growth Factor beta1

Identifiers

PMID20142324
PMCPMC2857041
OpenAlexW2016436468

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.